Oxaliplatin vs Cisplatin in Chemoradiotherapy of Head and Neck Cancer

Comparison Between Oxaliplatin and Cisplatin Based Concurrent Chemo Radiotherapy in Locally Advanced Head and Neck Cancer: A Randomised Controlled Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/01/017198

Enrollment

Registered

2019-01-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

Intervention1: Oxaliplatin Chemoradiotherapy: Concurrent chemoradiation with weekly Oxaliplatin 50 mg/m2 (maximum of 75mg) for 6 weeks. Control Intervention1: Cisplatin Chemoradiotherapy: Concurrent c

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed locally advanced head and neck squamous cell cancers. 2. Stage III-IVB by AJCC Cancer Staging Manual Eight Edition, 2017. 3. Primary tumour sites in oral cavity, oropharynx, hypopharynx and larynx. 4. Age >18 years and 5. Eastern Cooperative Oncology Group (ECOG) performance status of â?¤2. 6. Haemoglobin > 10g/L. 7. Total Leucocyte count > 4,000/cumm. 8. Platelet count > 1,00,000/cumm. 9. Bilirubin 10. Normal Serum creatinine and Blood Urea. 11. Patients who had not received prior chemotherapy and/or radiotherapy.

Exclusion criteria

Exclusion criteria: 1. Synchronous malignancy. 2. Previously diseased salivary gland. 3. Patients with history of neuropathy e.g. Diabetic neuropathy 4. Patients with Congestive cardiac failure. 5. Patients with uncontrolled hypertension. 6. Patients not willing for concurrent chemoradiotherapy.

Design outcomes

Primary

Measure	Time frame
% of tumour responseTimepoint: 3 months and 6 months	—

Secondary

Measure	Time frame
To compare disease control at 6 months with concurrent chemoradiotherapy using oxaliplatin versus concurrent chemoradiotherapy using cisplatin in locally advanced non-nasopharyngeal head and neck cancer.Timepoint: 6 months;To compare the toxicity profile of concurrent chemoradiotherapy using oxaliplatin versus concurrent chemoradiotherapy using cisplatin in locally advanced non-nasopharyngeal head and neck cancers.Timepoint: Weekly review during treatment. ;Compliance of concurrent oxaliplatin with radiotherapy in locally advanced non-nasopharyngeal head and neck cancer.Timepoint: During treatment	—

Measure

Time frame

To compare disease control at 6 months with concurrent chemoradiotherapy using oxaliplatin versus concurrent chemoradiotherapy using cisplatin in locally advanced non-nasopharyngeal head and neck cancer.Timepoint: 6 months;To compare the toxicity profile of concurrent chemoradiotherapy using oxaliplatin versus concurrent chemoradiotherapy using cisplatin in locally advanced non-nasopharyngeal head and neck cancers.Timepoint: Weekly review during treatment. ;Compliance of concurrent oxaliplatin with radiotherapy in locally advanced non-nasopharyngeal head and neck cancer.Timepoint: During treatment

—

Countries

India

Contacts

Public ContactYanpothung Yanthan

AIIMS Rishikesh

drrajesh_pasricha@yahoo.com7055701703

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026